# Cogent Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cogent-biosciences

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.cogentbio.com
- Total disclosed funding: $71M
- Latest round: Series B (Jun 11, 2015)
- Investors on record: 12

## About

Based in Massachusetts, US, and founded in 2014 and led by CEO Andrew Robbins, Cogent Biosciences, Inc. operates as a biopharmaceutical company that develops cellular immunotherapies for the treatment of cancer. As of 2024, the company is traded at Nasdaq exchange with ticker symbol COGT. In February 2024, Cogent Biosciences, Inc. raised USD 225 million in PIPE funding led by Commodore Capital, with participation from Fairmount Funds Management, Venrock Healthcare Capital Partners. 

Cogent Biosciences, Inc. developed a product known as bezuclastinib, which is a selective inhibitor targeting exon 17 mutations within the KIT receptor tyrosine kinase, including the KIT D816V mutation. It supports mutation in Systemic Mastocytosis, a rare disease characterized by the accumulation of mast cells in various organs. The company’s product also developed for advanced gastrointestinal stromal tumors (GIST), which are for oncogenic KIT signaling. In addition, the firm’s drug is in early clinical results in Phase 1/2 trials, for treating cancer. 

The company plans to use the funding from February 2024 to fund research and development, activities relating to bezuclastinib and other product candidates, as well as for working capital and general corporate purposes.

## Funding rounds

- Series B, Jun 11, 2015, $65M — Atlas Venture, New Leaf Venture Partners, F-Prime Capital, Wellington Management, Sanofi Ventures, Jennison Associates, Sectoral Asset Management, Novo Holdings, Seagen, Inc., Cowen Inc., Brace Pharmaceuticals, Sabby Capital
- Series A, Oct 3, 2014, $6.3M — Atlas Venture, F-Prime Capital, Sanofi Ventures

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series B
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A, Series B
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series A, Series B
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series B
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series B
- Jennison Associates — Series B
- Sectoral Asset Management (https://capitalatlas.ai/funds/sectoral-asset-management) — Series B
- Novo Holdings — Series B
- Seagen, Inc. — Series B
- Cowen Inc. — Series B
- Brace Pharmaceuticals — Series B
- Sabby Capital (https://capitalatlas.ai/funds/sabby-capital) — Series B